MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Kodu・Aktsiate loetelu・Editas Medicine Inc

Editas Medicine Inc

Suletud

SektorTervishoid

1.6 3.23

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.49

Max

1.61

Põhinäitajad
By Trading Economics
Sissetulek	17M -45M
Müük	31M 31M
Aktsiakasum	-0.55
Kasumimarginaal	-148.33
Töötajad	246
EBITDA	28M -33M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+101.28% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2025

Turustatistika
By TradingEconomics
Turukapital	-35M 111M
Eelmine avamishind	-1.63
Eelmine sulgemishind	1.6

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

1.3 / 1.56 Toetus ja vastupanu

Editas Medicine Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2025, 23:54 UTC

Kuumad aktsiad

Stocks to Watch: Alphabet, Intel, AppFolio

24. apr 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24. apr 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. apr 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24. apr 2025, 23:37 UTC

Peamised uudised

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24. apr 2025, 23:36 UTC

Peamised uudised

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24. apr 2025, 23:13 UTC

Peamised uudised

Tulu

Google's Earnings Power Holds Up in Global Turbulence -- Update

24. apr 2025, 23:09 UTC

Peamised uudised

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24. apr 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24. apr 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24. apr 2025, 22:51 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24. apr 2025, 22:48 UTC

Peamised uudised

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24. apr 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24. apr 2025, 22:38 UTC

Market Talk

Tulu

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24. apr 2025, 22:24 UTC

Tulu

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24. apr 2025, 22:24 UTC

Tulu

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24. apr 2025, 22:24 UTC

Market Talk

Tulu

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24. apr 2025, 22:23 UTC

Tulu

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24. apr 2025, 22:11 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

24. apr 2025, 22:11 UTC

Market Talk

Tulu

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24. apr 2025, 22:09 UTC

Peamised uudised

Tulu

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24. apr 2025, 22:00 UTC

Market Talk

Tulu

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24. apr 2025, 21:39 UTC

Peamised uudised

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24. apr 2025, 21:24 UTC

Peamised uudised

Tulu

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24. apr 2025, 21:24 UTC

Peamised uudised

Tulu

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24. apr 2025, 21:23 UTC

Peamised uudised

Tulu

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24. apr 2025, 21:04 UTC

Tulu

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24. apr 2025, 21:03 UTC

Tulu

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24. apr 2025, 21:03 UTC

Tulu

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24. apr 2025, 21:02 UTC

Tulu

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Võrdlus sarnastega

Hinnamuutus

Editas Medicine Inc Prognoos

Hinnasiht

By TipRanks

101.28% tõus

12 kuu keskmine prognoos

Keskmine 3.14 USD 101.28%

Kõrge 5 USD

Madal 1 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Editas Medicine Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Editas Medicine Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.3 / 1.56Toetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

There are no events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.